In the latest trading session, 1.05 million Anavex Life Sciences Corporation (NASDAQ:AVXL) shares changed hands as the company’s beta touched 0.70. With the company’s most recent per share price at $10.38 changed hands at -$0.85 or -7.54% at last look, the market valuation stands at $880.68M. AVXL’s current price is a discount, trading about -39.11% off its 52-week high of $14.44. The share price had its 52-week low at $3.25, which suggests the last value was 68.69% up since then. When we look at Anavex Life Sciences Corporation’s average trading volume, we note the 10-day average is 3.06 million shares, with the 3-month average coming to 1.78 million.
Analysts gave the Anavex Life Sciences Corporation (AVXL) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.00. If we narrow down to specifics, the data shows that 0 out of 6 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended AVXL as a Hold, 4 felt it is a Buy and 0 rated the stock as Underweight. Anavex Life Sciences Corporation’s EPS for the current quarter is expected to be -0.17.
Anavex Life Sciences Corporation (NASDAQ:AVXL) trade information
Instantly AVXL was in red as seen in intraday trades today. With action -15.92%, the performance over the past five days has been red. The company’s shares are showing year-to-date downside of -3.32%, with the 5-day performance at -15.92% in the red. However, in the 30-day time frame, Anavex Life Sciences Corporation (NASDAQ:AVXL) is 23.91% up. Looking at the short shares, we see there were 19.69 million shares sold at short interest cover period of 10.82 days.
The consensus price target for the stock as assigned by Wall Street analysts is 11, meaning bulls need an upside of 5.64% from its recent market value. According to analyst projections, AVXL’s forecast low is 11 with 11 as the target high. To hit the forecast high, the stock’s price needs a -5.97% plunge from its current level, while the stock would need to soar -5.97% for it to hit the projected low.
Anavex Life Sciences Corporation (AVXL) estimates and forecasts
Data shows that the Anavex Life Sciences Corporation share is performing relatively much not better than most of its peers within the same industry. As can be gleaned from the statistics, the company’s share value shot 92.64% over the past 6 months, a -40.38% in annual growth rate that is considerably lower than the industry average of 16.40%.
According to analysts, the company will likely register a growth in its current quarter sales, forecast at 0.00%. The estimates for the next quarter sales put growth at 0.00%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 0.85%. The 2025 estimates are for Anavex Life Sciences Corporation earnings to decrease by -16.03%.
AVXL Dividends
Anavex Life Sciences Corporation is expected to release its next quarterly earnings report in February.
Anavex Life Sciences Corporation (NASDAQ:AVXL)’s Major holders
If we look at who the major shareholders are, we find that insiders hold 3.05% of Anavex Life Sciences Corporation shares while 32.04% of the shares are in the hands of institutional holders. The share float percentage for the stock currently stands at 33.04%. There are 32.04% institutions holding the Anavex Life Sciences Corporation stock share, with BLACKROCK INC. the top institutional holder. As of 2024-06-30, the company held 7.7506% of the shares, roughly 6.39 million AVXL shares worth $26.97 million.
VANGUARD GROUP INC holds the second largest percentage of outstanding shares, with 5.5154% or 4.55 million shares worth $19.19 million as of 2024-06-30.
Among Mutual Funds, the top two as of Sep 30, 2024 were Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF. With 2.53 shares estimated at $25.85 million under it, the former controlled 2.99% of total outstanding shares. On the other hand, iShares Russell 2000 ETF held about 2.29% of the shares, roughly 1.95 shares worth around $19.85 million.
